Skip to content

Development of an optimal program for the rehabilitation of cancer patients after chemotherapy

Development of an optimal program for the rehabilitation of cancer patients after chemotherapy - Development of an optimal program for cancer patients after chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31213
Enrollment
250
Registered
2008-08-12
Start date
2008-08-12
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nieuwvormingen, (1)bijwerkingen inherent aan de behandeling: chemotherapie en bestraling. (2)Deconditionering cancer deconditioning side effect

Interventions

the intervention consist of a physical part during 18 weeks and a psychological part. First 12 weeks the accent lies on strength training with exercises for different muslce groups. From week 13 unt

Sponsors

Máxima Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with cancer with curative treatment with chemotherapy in Maxima Medical Centrum Veldhoven. Chemotherapy at least 6 weeks and maximal 52 weeks Motivated to follow the program Be able to follow the program under profesional supervision Logistic possible to follow the program age 18-65 years, treated with chemotherapy from 2001, no co-morbidity

Exclusion criteria

Exclusion criteria: In general daily life dependent of care Low physical capacity (sitting, laying and under 100 meter walking) Cognitive disturbances or emotional very weak Severe side effects of medication Other severe diseases responsible for physical activity intolerance

Design outcomes

Primary

MeasureTime frame
Physical capacity (muscle strength and condition), body composition, fatigue, quality of life and feeding.

Secondary

MeasureTime frame
not of application

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)